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BACKGROUND & AIMS: AJM300 is an orally active small-
molecule antagonist of the a4 integrin subunit. We performed
a randomized trial to investigate the efﬁcacy and safety of
AJM300 in patients with active ulcerative colitis (UC).
METHODS: In a double-blind, placebo-controlled, phase 2a
study, 102 patients with moderately active UC (Mayo Clinic
scores of 610, endoscopic subscores 2, and rectal bleeding
subscores 1) who had inadequate response or intolerance to
mesalamine or corticosteroids were randomly assigned to
receive AJM300 (960 mg) or placebo 3 times daily for 8 weeks.
The primary end point was a clinical response at week 8,
deﬁned as a decrease in Mayo Clinic score of at least 3 points
and a decrease of at least 30% from baseline, with a decrease in
the rectal bleeding subscore of at least 1 point or an absolute
rectal bleeding subscore of 0 or 1. RESULTS: Clinical response
rates were 62.7% and 25.5% at week 8 in the AJM300 group
and placebo group, respectively (odds ratio [OR] ¼ 5.35; 95%
conﬁdence interval [CI]: 2.2312.82; P ¼ .0002). Rates of
clinical remission (Mayo Clinic score 2 and no subscore >1)
were 23.5% and 3.9% in the AJM300 group and placebo
groups, respectively (OR ¼ 7.81; 95% CI: 1.6437.24;
P ¼ .0099), and rates of mucosal healing (endoscopic subscores
of 0 or 1) were 58.8% and 29.4% (OR ¼ 4.65; 95% CI:
1.8111.90; P ¼ .0014). No serious adverse event, including
progressive multifocal leukoencephalopathy, was observed,
although more investigations are needed to conﬁrm the safety
proﬁle of this drug. CONCLUSIONS: AJM300 was well tolerated
and more effective than placebo in inducing clinical response,
clinical remission, and mucosal healing in patients with
moderately active UC. ClinicalTrials.jp no: JapicCTI-132293.*Authors share co-ﬁrst authorship.
Abbreviations used in this paper: CI, conﬁdence interval; IBD, inﬂamma-
tory bowel disease; JCV, John Cunningham virus; MAdCAM-1, mucosal
addressin cell adhesion molecule-1; OR, odds ratio; PML, progressive
multifocal leukoencephalopathy; TNF, tumor necrosis factor; UC, ulcera-
tive colitis.Keywords: Integrin; IBD; Randomized Clinical Trial;
Lymphocyte Trafﬁcking.
nﬂammatory bowel disease (IBD)—the main forms ofMost current article
© 2015 by the AGA Institute
0016-5085
http://dx.doi.org/10.1053/j.gastro.2015.08.044
Open access under CC BY-NC-ND license.Iwhich are Crohn’s disease and ulcerative colitis
(UC)—is a chronic inﬂammatory disease of the gastroin-
testinal tract. Although the cause of the disease remains
unknown, the inﬁltration of lymphocytes into the laminapropria at the sites of inﬂammation is a well-documented
pathogenic mechanism of IBD.1,2 Inﬁltration of lympho-
cytes is accelerated by increased expression of adhesion
molecules, such as vascular cell adhesion molecule-1 and
mucosal addressin cell adhesion molecule-1 (MAdCAM-1)
on the surface of endothelial cells at the site of inﬂammatory
lesions.3,4 The binding of lymphocytes to vascular cell
adhesion molecule-1 or MAdCAM-1 requires the expression
of a4b1 or a4b7 integrin on lymphocytes, respectively.
Vascular cell adhesion molecule-1 is expressed on the
luminal surface of endothelium in numerous types of tis-
sues, and MAdCAM-1 is expressed predominantly in the
intestinal lamina propria.4,5
Several clinical studies have demonstrated that a4
integrin blockade is clinically effective as a therapeutic
approach for IBD, for example, anti-a4 integrin antibody,
natalizumab,6,7 or anti-a4 b7 integrin antibody, vedolizu-
mab.8,9 Furthermore, anti-b7 integrin antibody, etrolizu-
mab,10 and antiMAdCAM-1 antibodies11 are being
developed for the treatment of IBD. However, all the agents
are biologics and raise some concerns regarding the long-
term administration. Adverse effects speciﬁcally related to
biologics have been observed in the treatment with anti-
tumor necrosis factora (TNFa) antibodies,12 such as
immunogenicity, infusion reaction, and the loss of efﬁcacy
related to the production of antidrug antibodies. Therefore,
the development of orally active chemical medicine is a
reasonable and preferable approach. Although several
small-molecule a4 integrin antagonists have been studied in
clinical trials for the treatment of asthma and multiple
sclerosis,13–15 there are no reports on the efﬁcacy of oral a4
integrin antagonist in patients with IBD.
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ATAJM300 is a novel, orally active, small-molecule a4
integrin antagonist that is classiﬁed as a phenylalanine de-
rivative16 and is currently being developed for IBD.17,18 In
animal models, an oral treatment with AJM300 inhibited the
lymphocyte from homing to the gut, and prevented the
development of experimental colitis in mice.19 Orally
administrated AJM300 can be absorbed through the intestine,
distributed to various tissues through systemic blood circu-
lation, and excreted mainly into the feces. The pharmacody-
namics of a4 integrin antagonist are well known to increase
the peripheral lymphocyte counts, probably due to inhibition
of lymphocyte attachment to the vascular endothelium. For
AJM300, the increase in peripheral lymphocyte counts
was maintained throughout the day at a 960-mg dosage, but
not at a 480-mg dosage, 3 times daily in healthy volunteers.
Progressive multifocal leukoencephalopathy (PML) is a
side effect of anti-a4 integrin therapy. PML is an opportu-
nistic brain infection that is caused by the John Cunningham
virus (JCV), and usually leads to death or severe disability.
Natalizumab is currently available through a special
restricted distribution program to mitigate the risk of PML
in clinical practice. The clinical development of oral a4
integrin antagonists also needs to minimize the potential
risk of PML carefully. Therefore, we designed the 8-week,
placebo-controlled trial to investigate the efﬁcacy and safety
of AJM300 as remission induction therapy in patients with
moderately active UC, under the study protocol to mitigate
the potential risk of PML.Methods
Ethics Statement
The study was approved by the Institutional Review Board
at each center and conducted in accordance with the Good
Clinical Practice, other relevant rules and regulations, and
Helsinki declaration. All patients provided written informed
consent. All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Study Design and Patients
This was a randomized, double-blind, placebo-controlled,
phase 2a study, conducted at 42 medical centers in Japan be-
tween May 2012 and July 2013 (ClinicalTrials.jp number:
JapicCTI-132293). This study was conducted to obtain infor-
mation on the efﬁcacy and safety proﬁle of AJM300 as induction
therapy in patients with moderately active UC. The target
number was 60 patients per group, 120 in total.
Eligible patients were 20 to 65 years of age with a diagnosis
of moderately active UC, with the Mayo Clinic score20 of 610, a
rectal bleeding subscore of 1 or higher, and an endoscopic sub-
score of 2 or higher. Additional inclusion criteria were docu-
mentation of inadequate response or intolerance to mesalamine
(4.0 g or higher of salazosulfapyridine, 4.0 g Pentasa, or 3.6 g
Asacol per day) and/or corticosteroids (3040 mg of oral
prednisolone or the equivalent per day). Patients continued to
take mesalamine at a constant dose for at least 4 weeks or
prednisolone for at least 2 weeks before enrollment. Although
concomitant oral mesalamine was administrated at a constant
dose throughout the study, concomitant corticosteroid dose wasallowed to taper within 5 mg per 2 weeks, according to a pre-
deﬁned regimen for patients showing any clinical response to the
study drug. Patients were ineligible if they had received azathi-
oprine or 6-mercaptopurine within 8 weeks before enrollment,
or TNF antagonists, cyclosporine, tacrolimus, or methotrexate
within 12 weeks before enrollment. Rectal therapy with mesal-
amine or corticosteroids, as well as leukocytapheresis, was dis-
continued 4 weeks before enrollment. Other criteria for
exclusion included proctitis, corticosteroid dependence, severe
colonic stricture, infectious enteritis, a history of bowel surgery,
major organ dysfunction, malignant neoplasm, drug hypersen-
sitivity or dependence, alcoholism, psychiatric symptom, preg-
nancy or lactation, and a white blood-cell count 3.0  103/mL,
concomitant use of immunosuppressants (eg, azathioprine,
6-mercaptopurine, cyclosporine, methotrexate, or tacrolimus),
and the presence of neurologic symptoms (eg, motor paralysis,
impaired vision, alogia, symptoms of dementia, and facial nerve
palsy) for an increased potential risk of PML.Randomization and Blinding
Patients were randomized to the active treatment group or
placebo group in a 1:1 ratio by dynamic balancing allocation
with minimization method based on the strata of the inade-
quate response or intolerance to mesalamine and/or cortico-
steroids and the baseline Mayo Clinic score (67 or 810).
Randomization was performed centrally. Patients, assessing
physicians, and the funder were blinded to the assignment of
treatment throughout the study.Study Procedures
Patients were assigned to receive either AJM300 960 mg or
placebo 3 times daily for 8 weeks. The dose regimen of AJM300
was determined according to the following data from the phase
1 multiple oral dose study (data not shown). For pharmacoki-
netics, although the drug exposure (maximum serum concen-
tration and area under the concentration-time curve) was
mostly saturated at the 480 mg 3 times daily dosage, the
trough drug concentration in plasma was higher with the
960 mg 3 times daily dosage than the 480 mg 3 times daily
dosage. In addition, the pharmacologic activity of AJM300
(surrogated by the increase in peripheral lymphocyte count)
was maintained throughout the day at the 960 mg 3 times daily
dosage, but not at the 480 mg 3 times daily dosage.
The patients visited at weeks 0, 2, 4, and 8. At each visit, a
partial Mayo Clinic score (excluding endoscopic subscore) was
calculated, adverse events were noted, and neurologic symptom
questionnaires were administrated. Blood samples for hemato-
logic testing were obtained at each visit. The peripheral
lymphocyte counts at weeks 0, 2, 4, and 8 was measured as the
pharmacodynamics parameter, and neutrophil counts were
assessed to investigate the effect on leukocytes lacking a4
integrin. Atweek8 only, administration ofAJM300 or placebowas
terminated in the morning on the day before the last visit, for the
purpose of conﬁrmation of the recovery of pharmacodynamics.
Pharmacokinetics measurement was not performed in this study.
Colonoscopy or sigmoidscopy was performed at baseline
and week 8 with biopsy. Endoscopic subscores were assessed
primarily by the on-site investigators. The central evaluation
committee for colonoscopy was established to assure the reli-
ability of the assessment by the on-site investigators.
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The primary end point was a clinical response, deﬁned as a
decrease in the Mayo Clinic score of at least 3 points and
a decrease of at least 30% from the baseline score, with a
decrease of at least 1 point on the rectal bleeding subscore or
an absolute rectal bleeding subscore of 0 or 1. The main sec-
ondary end points were clinical remission, deﬁned as a Mayo
Clinic score of 2 or lower and no subscore higher than 1 and
mucosal healing, deﬁned as an endoscopic subscore of 0 or 1,
and partial Mayo Clinic score. The endoscopic subscores
assessed by the on-site investigators (investigator or sub-
investigator) were applied to the Mayo Clinic score. The on-site
investigators evaluated and determined the most severely
affected site up to the sigmoid colon from the anus at week 0,
and evaluated the same site at week 8. In addition, the endo-
scopic subscores were also evaluated by the central evaluation
committee for endoscopic evaluation to assure the reliability of
the evaluation by the on-site investigators. The on-site in-
vestigators collected 2 biopsy specimens of colonic mucosal
tissue in the marginal region of the most severely affected site
during colonoscopy at week 0 and in the same region at week 8.
Histologic activity was evaluated using the Riley score21 by the
central evaluation committee for histopathologic evaluation.
Safety evaluations, which included all reports of adverse
events and clinical laboratory tests, were conducted throughout
the study. The investigators and the sponsor were not informed
of the patients’ differential counts of white blood cells, so that
the increase in circulating lymphocyte counts observed in the
active treatment group would not lead to unblinding of the
treatment assignments.
For all patients, new occurrence of neurologic signs and
symptoms potentially consistent with PML were assessed
cautiously throughout the study using the standardized ques-
tionnaires. If PML-related signs or symptoms were suspected,
administration of the study drug was immediately terminated.
Neurologic examination using magnetic resonance imaging
scans and polymerase chain reaction analyses was available as
necessary. An independent safety assessment committee con-
sisting of a panel of PML experts was organized to secure the
patient’s safety against the onset of PML and to provide a
further guidance for the on-site investigators and the sponsor.
Statistical Analysis
The full analysis set, which consisted of all patients who
were randomized, received at least 1 dose of study drug, and
had at least 1 available efﬁcacy data point, was used for the
analysis of efﬁcacy. The safety analysis set, which consisted of
all patients who were randomized and received at least 1 dose
of study drug, was used for the analysis of safety. The last
observation carried forward method was used for statistical
analyses on the efﬁcacy variables to handle of the missing data,
especially for withdrawal. On the other hand, for the safety
variables, the imputation methods were not used. The primary
end point was analyzed by the logistic regression model after
adjustment for inadequate response or intolerance to mesal-
amine and/or corticosteroids, and baseline Mayo Clinic score
(67 or 810) to compare the clinical response between the
treatment groups. Additionally, the proportion of patients who
had good clinical response in each treatment group and its
difference between the treatment groups were calculated. The
secondary end point, clinical remission, was analyzed by thelogistic regression model after adjustment for the baseline
Mayo Clinic score (67 or 810). Mucosal healing was
analyzed by logistic regression model, after adjustment for the
inadequate response or intolerance to mesalamine and/or
corticosteroids and baseline Mayo Clinic score (67 or 810).
The proportions of patients in clinical remission and patients
with mucosal healing were calculated by treatment group.
Summary statistics of the change from baseline in the partial
Mayo Clinic score and the peripheral lymphocyte counts at each
evaluation time were calculated by treatment group. A t test
was used to compare the change in the partial Mayo Clinic
scores and the peripheral lymphocyte counts between the 2
treatment groups. For evaluating safety, the adverse events
were tabulated by treatment group. All statistical tests were
conducted at the .05 level of signiﬁcance (2-sided). No adjust-
ment was made for multiple comparisons.
The determination of sample size was based on the
following calculations. The clinical response rate was estimated
to be 54.8% to 66.0% for the active treatment group, and
33.0% to 35.6% for the placebo group. The number of subjects
required to provide power of 80% with 2-sided signiﬁcance
level of 5% was computed.Results
Randomization and Baseline Characteristics
Of 127 patients that gave informed consent, 3 patients
withdrew from the study before randomization. After
excluding 22 patients who did not meet inclusion criteria or
met exclusion criteria, 102 patients underwent randomiza-
tion. Those patients were randomly assigned to receive the
active treatment (AJM300) or placebo (51 patients for each)
(Figure 1). Study treatment was started in all 102 patients.
The full analysis set was equivalent to the safety analysis
set. Demographics and baseline characteristics were similar
between the placebo and active treatment groups (Table 1).
In the 102 randomized patients, the therapeutic outcomes of
the current relapse were an inadequate response to
mesalamine (n ¼ 92 [90.2%]), intolerance to mesalamine
(n ¼ 3 [2.9%], inadequate response to corticosteroid (n ¼ 3
[2.9%]), and intolerance to corticosteroids (n ¼ 4 [3.9%]).
Efﬁcacy
A total of 32 of 51 patients receiving the active treatment
(62.7%) and 13 of 51 patients receiving placebo (25.5%)
had a clinical response at week 8 (OR ¼ 5.35; 95% CI:
2.2312.82; logistic regression, P ¼ .0002) (Figure 2). A
total of 12 patients receiving the active treatment (23.5%)
and 2 receiving placebo (3.9%) had clinical remission
(OR ¼ 7.81; 95% CI: 1.6437.24; logistic regression;
P ¼ .0099). Proportions of patients with mucosal healing
were 58.8% (30 of 51 patients) with the active treatment
and 29.4% (15 of 51 patients) with placebo (OR ¼ 4.65;
95% CI: 1.8111.90; logistic regression, P ¼ .0014)
(Figure 2). The efﬁcacy of the active treatment was gener-
ally consistent across subgroups (Supplementary Figure 1).
The proportion of patients achieving endoscopic sub-
score of 0 at week 8 was also higher in the active treatment
group than that in the placebo group, although the
Figure 1. Enrollment and
treatment. In the study, a
total of 102 patients with
ulcerative colitis were
randomly assigned to
receive placebo (n ¼ 51) or
AJM300 (n ¼ 51).
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ATdifference was not statistically signiﬁcant (15.7% vs 5.9% in
the active treatment group and placebo group, respectively;
difference, 9.8; 95% CI: 2.7 to 22.7). The signiﬁcant efﬁ-
cacies of the active treatment (clinical response, clinical
remission, and mucosal healing) were also conﬁrmed by theTable 1.Demographics and Baseline Characteristics
Characteristic Placebo (n
Age, y 42.6 ±
Male sex, n (%) 26 (51
Body weight, kg 60.7 ±
Current smoker, n (%) 3 (5.
Duration of disease, y 9.3 ±
C-reactive protein, mg/dL 0.60 ±
Disease extent, n (%)
Left sided 31 (60
Pancolitis or extensive 20 (39
Mayo Clinic scorea 7.7 ±
Score 67, n (%) 22 (43
Score 810, n (%) 29 (56
Components of Mayo Clinic scorea
Stool frequency subscore 2.0 ±
Rectal bleeding subscore 1.6 ±
Endoscopic subscore 2.2 ±
Physician’s global assessment subscore 1.9 ±
Riley scoreb 11.8 ±
Response to treatment of current relapse, n (%)
Inadequate response to mesalamine 46 (90
Intolerance to mesalamine 1 (2.
Inadequate response to corticosteroids 1 (2.
Intolerance to corticosteroids 3 (5.
NOTE. Values are mean ± SD unless indicated otherwise.
aThe Mayo Clinic score ranges from 0 to 12, with higher scores
0 to 3.
bThe Riley score ranges from 0 to 18, with higher scores indicaassessment of the central evaluation committee for endo-
scopic evaluation as well (data not shown). Consistency of
the endoscopic subscores between the on-site investigators
and the central evaluation committee was 64% at baseline
and 59% for outcome measures.¼ 51) AJM300 (n ¼ 51) Total (n ¼ 102)
13.4 41.7 ± 11.4 42.2 ± 12.4
.0) 31 (60.8) 57 (55.9)
12.0 62.0 ± 11.3 61.4 ± 11.6
9) 4 (7.8) 7 (6.9)
8.9 8.6 ± 9.2 9.0 ± 9.0
1.16 0.50 ± 0.82 0.55 ± 1.00
.8) 29 (56.9) 60 (58.8)
.2) 22 (43.1) 42 (41.2)
1.2 7.8 ± 1.2 7.8 ± 1.2
.1) 20 (39.2) 42 (41.2)
.9) 31 (60.8) 60 (58.8)
0.8 2.1 ± 0.8 2.1 ± 0.8
0.6 1.6 ± 0.6 1.6 ± 0.6
0.4 2.1 ± 0.3 2.1 ± 0.4
0.2 1.9 ± 0.2 1.9 ± 0.2
3.3 11.8 ± 2.8 11.8 ± 3.0
.2) 46 (90.2) 92 (90.2)
0) 2 (3.9) 3 (2.9)
0) 2 (3.9) 3 (2.9)
9) 1 (2.0) 4 (3.9)
indicating more severe disease. Each subscore ranges from
ting more severe disease.
Figure 2. Proportion of patients with a clinical response, in clinical remission, and with mucosal healing at week 8. A clinical
response was deﬁned as a reduction in the Mayo Clinic score of at least 3 points and a decrease of at least 30% from the
baseline score, with a decrease of at least 1 point on the rectal bleeding subscore or an absolute rectal bleeding subscore of
0 or 1. Clinical remission was deﬁned as a Mayo Clinic score of 2 or lower and no subscore higher than 1. Mucosal healing was
deﬁned as an absolute endoscopic subscore of 0 or 1. The logistic regression model adjusted for the inadequate response or
intolerance with mesalamine and/or corticosteroids, and the baseline Mayo Clinic score (67 or 810) was used for the
statistical analysis of clinical response and mucosal healing. For the clinical remission, the logistic regression model adjusted
for the baseline Mayo Clinic score (67 or 810) was used.
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improvement in the partial Mayo Clinical score compared
with patients receiving placebo (Figure 3). Each subscore
(stool frequency, rectal bleeding, endoscopic ﬁndings, or
physician’s global assessment) of the Mayo Clinic score
improved signiﬁcantly in the active treatment group
compared with that in the placebo group at week 8
(Supplementary Table 1). In addition, the endoscopicFigure 3. Change from baseline in the partial Mayo Clinic
score. The partial Mayo Clinic score consists of the Mayo
Clinic score minus the endoscopic subscore; ranging 0 to 9,
with higher scores indicating more severe disease. The
change from baseline in the partial Mayo Clinic score at each
visit (weeks 2, 4, and 8) was indicated by the mean value with
SD. Asterisk denotes signiﬁcant difference between treatment
groups at each visit (t test, *P < .05; **P < .01).improvement was accompanied by a signiﬁcant histologic
improvement in the Riley score (Supplementary Table 2).
Pharmacodynamics
Anti-a4 integrin therapeutic agents are known to in-
crease peripheral blood total lymphocyte counts. The sig-
niﬁcant increase in peripheral lymphocyte counts (as the
pharmacodynamic action of AJM300) was observed at week
2 (mean, 2.7  103/mL vs 1.8  103/mL in the active
treatment group and placebo group, respectively; differ-
ence, 0.8  103/mL; 95% CI: 0.5 to 1.2  103), as well as
week 4 (mean, 2.7  103/mL vs 1.8  103/mL; difference,
1.0  103/mL; 95% CI: 0.6 to 1.3  103) (Figure 4). At week
8, the day after last administration of the active treatment,
the pharmacodynamic action disappeared (mean, 2.0 
103/mL vs 1.8  103/mL; difference, 0.2  103/mL; 95%
CI: 0.1 to 0.5  103). As for the effect on leukocytes
lacking a4 integrin, no change in neutrophil counts was
observed throughout the study (data not shown).
Safety
Data for all randomized patients were used for the safety
analysis. No important differences were observed between
the treatment groups in the incidence of adverse events,
49.0% (25 of 51 patients) in the active treatment group and
56.9% (29 of 51 patients) in the placebo group (Table 2).
The grades of all the adverse events were mild or moderate
in severity, and no serious adverse events were observed in
this study. The most common adverse events were naso-
pharyngitis and UC. The incidence of nasopharyngitis was
similar between the treatment groups, 9.8% (5 of 51 pa-
tients) in the active treatment group and 7.8% (4 of 51
Figure 4. Peripheral lymphocyte counts. Peripheral lympho-
cyte counts of patients with active UC before and after
receiving placebo or AJM300. Blood sampleswere obtained at
weeks 0, 2, 4 and8.Studydrug treatmentwas terminated in the
morning on the day before the last visit (week 8) to conﬁrm the
disappearance of the pharmacological activity of AJM300
at week 8. Bars are ±SD, and asterisk denotes signiﬁcant dif-
ference between treatment groups at each evaluation time
(t test, P < .05).
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to UC were higher in the placebo group (17.6%; 9 of 51
patients) than those in the active treatment group (3.9%; 2
of 51 patients). Adverse events leading to discontinuation of
the study drug included exacerbation of UC (1 patient in the
active treatment group and 8 in the placebo group) and
abnormality of liver function (1 patient in the placebo
group). The incidence of drug-related adverse events was
21.6% (11 of 51 patients) in the active treatment group and
7.8% (4 of 51 patients) in the placebo group, all of whichTable 2.Summary of Adverse Events
Event
Placebo
All S
Any adverse events 29 (56.9)
Discontinued because of adverse event 9 (17.6)
Serious adverse event 0
Adverse events 3% in any groups
Nasopharyngitis 4 (7.8)
Headache 1 (2.0)
Upper respiratory tract inﬂammation 3 (5.9)
Ulcerative colitis 9 (17.6)
Nausea 1 (2.0)
Abdominal bloating 2 (3.9)
Upper abdominal pain 2 (3.9)
Blood amylase increased 0
Blood lactate dehydrogenase increased 0
C-reactive protein increased 1 (2.0)
White blood cell count increased 0were mild. There were no frequent drug-related adverse
events (>5.0%). Although higher incidences of drug-related
adverse events, particularly abnormalities in the laboratory
test values, were observed in the active treatment group
than in the placebo group, these changes were mild and
recovered without any treatment. Overall, infection, neuro-
logic symptom, or onset of PML was not observed in this
study.Discussion
This is the ﬁrst study to demonstrate the clinical beneﬁt
of an orally active small-molecule a4 integrin antagonist for
UC. In this phase 2a study, AJM300 960 mg 3 times daily
signiﬁcantly improved clinical response and clinical remis-
sion at week 8 compared with placebo in patients with
moderately active UC. Subgroup analysis showed the ther-
apeutic beneﬁt of the active treatment regardless of disease
duration, extent of disease, and baseline Mayo Clinic scores.
A higher proportion of patients achieved mucosal healing in
the active treatment group compared with the placebo
group. Recent evidence has emphasized the importance of
mucosal healing as a treatment goal for UC.22 It has been
reported that the most favorable subsequent clinical out-
comes were observed in patients with early achievement of
endoscopic subscore of 0.23 There was a trend toward an
increase in the number of patients with endoscopic sub-
score of 0 in the active treatment group compared with the
placebo group. Furthermore, a signiﬁcantly better histologic
improvement at week 8 was obtained in patients treated
with the active treatment compared with those with
placebo.
Rationales for the development of AJM300 were the
achievements of the oral anti-a4 integrin therapy. Oral drug
formulations often provide good drug adherence and may
resolve some issues in biologic therapy. Adverse effectsOverall safety population (n ¼ 102), n (%)
(n ¼ 51) AJM300 (n ¼ 51)
tudy drug-related All Study drug-related
4 (7.8) 25 (49.0) 11 (21.6)
1 (2.0) 1 (2.0) 0
0 0 0
0 5 (9.8) 0
1 (2.0) 2 (3.9) 1 (2.0)
0 2 (3.9) 0
0 2 (3.9) 0
0 2 (3.9) 2 (3.9)
1 (2.0) 1 (2.0) 1 (2.0)
0 0 0
0 2 (3.9) 2 (3.9)
0 2 (3.9) 2 (3.9)
0 2 (3.9) 1 (2.0)
0 2 (3.9) 1 (2.0)
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infusion reaction, and loss of efﬁcacy related to the pro-
duction of antidrug antibodies, could be observed in the
clinical practice.12 Antibodies to inﬂiximab develop in 8%
60% of patients with IBD.12 The increase in the number of
patients with loss of response or intolerance might also be
observed during treatment with the anti-integrin antibodies
in the future.9,24 Orally active small-molecule medicine with
pharmacologic activity similar to biologics could be beneﬁ-
cial for patients with IBD by overcoming these problems of
biologics.
As for safety of AJM300, there was no serious adverse
event in this study. The incidence of adverse events in the
active treatment group was similar to that in the placebo
group. Only 1 patient (2.0%) receiving the active treatment
discontinued the study due to an adverse event, and 9 pa-
tients (17.6%) receiving placebo discontinued the study,
mainly due to aggravation of UC. All drug-related adverse
events were mild and self-limiting. Neither infection nor
neurologic symptom was observed.
The most concerning adverse event of a4 integrin
blockade is the development of PML, which is a demyelinating
disorder of the central nervous system caused by JCV infec-
tion and reactivation. PML occurs in severely immunocom-
promised patients, such as those with acquired immune
deﬁciency syndrome, and with use of immunosuppressants or
some biologics, and usually leads to death or severe disability.
As of February 2012, two hundred and twelve conﬁrmed PML
cases among 99,751 patients treated with natalizumab were
reported (2.1 cases per 1000 patients).25 Although no cases of
PML have yet been observed among approximately 500 IBD
patients and healthy volunteers treated with AJM300 for a
maximum of 8 weeks in the clinical studies, such short-term
safety data do not preclude the possibility of PML risk with
this agent. Clinical development of AJM300 should be care-
fully conducted under a risk-management program to miti-
gate the potential risk for PML.
Based on the large post-marketing surveillance data
derived from >100,000 natalizumab-treated patients, 2
especially important ﬁndings have been obtained about risk
factors for PML. First, no cases of PML have been observed
with the therapy for 8 months.26 Second, the risk of PML
was much lower among the patients who were negative for
anti-JCV antibodies than those who were positive (the
incidence of PML; 0/1000; 95% CI: 00.32 and 3.87/1,000;
95% CI: 2.915.05, respectively).25,26 A prospective study
further conﬁrmed that no cases of PML were observed in
natalizumab-treated patients who were negative for anti-
JCV antibodies.27 These data suggest that the potential
PML risk of AJM300 may be minimized by limiting treat-
ment duration to <8 months. In addition, the measurement
of the anti-JCV antibodies might provide information helpful
for deciding whether to continue treatment with this agent.
Currently, the clinical development of AJM300 should be
focused on induction therapy in active UC patients, with
PML risk stratiﬁcation by measurement of anti-JCV anti-
bodies. A long-term safety study should be conducted to
preclude a possible increased risk of PML with this agent.
The potential risk of PML should be mitigated by a specialrestricted distribution program under a risk-management
action plan in clinical practice as well as in clinical trials.
The patients who were in immunocompromised conditions
or treated with concomitant immunosuppressants or anti-
TNFa antibodies should be precluded. Furthermore, the
patients with any neurologic symptom should be precluded
to enable timely detection of new neurologic symptoms that
suggest PML development. In the event of suspected PML,
early removal of drug from the body might lead to more
acceptable outcomes of the complication.26,28 For instance, a
timely discontinuation of treatment with natalizumab fol-
lowed by plasma exchange and immunoadsorption has been
recommended.26,28 AJM300 may have an advantage in the
outcome of PML, because of extremely shorter duration of
pharmacodynamic action (within a day after the last dose in
this study) than natalizumab (approximately 4 months).29
However, careful monitoring and risk minimization strate-
gies for PML will still be required to use this drug.
We concluded that the dosage of 960 mg 3 times daily
was optimal, because this dose was well tolerated and
demonstrated the expected clinical efﬁcacy. Furthermore,
the increase in peripheral lymphocyte counts, which is one
of the pharmacologic activities of a4 integrin blockade, was
maintained throughout the day at this dose regimen.
This study has the following limitations: small sample
size (a total of 102 patients, 51 patients per group), a short
period of study drug medication (8 weeks), and extremely
low enrollment of an inadequate response or intolerance to
corticosteroids. There was no information on medical his-
tory regarding an inadequate response or intolerance to
corticosteroids, immunosuppressants, and anti-TNFa anti-
bodies. Larger or longer-term clinical trials are required to
conﬁrm the efﬁcacy and safety of AJM300.
Most of the patients enrolled in this study had an inad-
equate response to mesalamine. In the treatment of UC,
corticosteroids have been, for decades, the ﬁrst and almost
exclusive therapeutic option for such patients. Given the
diverse adverse effects of corticosteroids, reasonable alter-
natives to them have been desired. AJM300 can be admin-
istered on an outpatient basis without any infusion
equipment or instruction. Thus, AJM300 could be suitable
for induction therapy in patients with moderately active UC
refractory to mesalamine.
In conclusion, oral treatment with the small-molecule a4
integrin antagonist AJM300 was safe, well tolerated, and
more efﬁcacious than placebo for inducing clinical response,
clinical remission, and mucosal healing in patients with
moderately active UC in this study. AJM300 may become a
novel oral therapeutic option especially for patients who
had an inadequate response to mesalamine with moderately
active UC, and phase 3 study for induction therapy is
currently ongoing in Japan.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.08.044.
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Supplementary Figure 1. Subgroup analysis. Plot of risk differences (dots) and 95% CIs (horizontal bars) for comparing the
proportion of patients with clinical response between AJM300 and placebo at week 8 by baseline characteristics.
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Supplementary Table 1.Change from Baseline to Week 8 in the Mayo Clinic Score and Each Subscore
Placeboa AJM300a
Difference from
placebob 95% CI P valuec
Mayo Clinic score 1.87 ± 0.61 (44) 4.05 ± 0.60 (47) 2.18 ± 0.49 3.14 to 1.21 <.0001
Components
Stool frequency 0.36 ± 0.22 (51) 1.06 ± 0.22 (51) 0.70 ± 0.17 1.03 to 0.36 <.0001
Rectal bleeding 0.38 ± 0.23 (51) 0.96 ± 0.23 (51) 0.58 ± 0.18 0.93 to 0.22 .0016
Endoscopic ﬁndings 0.55 ± 0.18 (44) 1.01 ± 0.18 (47) 0.46 ± 0.15 0.75 to 0.17 .0024
Physician’s global
assessment
0.53 ± 0.16 (51) 0.96 ± 0.16 (51) 0.43 ± 0.13 0.67 to 0.18 .0009
aValues are least squares mean ± standard error (n).
bValues are least squares mean ± standard error.
cAnalysis of covariance models were adjusted for stratiﬁcation factors at randomization.
Supplementary Table 2.Change From Baseline to Week 8 in Riley Score and Each Subscore
Placeboa AJM300a
Difference from
placebob 95% CI P valuec
Riley score 0.94 ± 1.03 (40) 3.03 ± 1.01 (46) 2.09 ± 0.86 3.79 to 0.39 .0017
Histological features
Round cells in the lamina propria 0.47 ± 0.22 (42) 0.93 ± 0.21 (46) 0.46 ± 0.18 0.81 to 0.10 .012
Polymorphonuclear cells in the
lamina propria
0.33 ± 0.26 (42) 0.89 ± 0.25 (46) 0.56 ± 0.21 0.97 to 0.14 .0096
Mucin depletion 0.085 ± 0.251 (42) 0.50 ± 0.25 (46) 0.41 ± 0.21 0.82 to 0.0052 .047
Crypt abscesses 0.31 ± 0.26 (42) 0.65 ± 0.25 (46) 0.34 ± 0.21 0.77 to 0.086 .12
Surface epithelial integrity 0.38 ± 0.30 (42) 0.16 ± 0.29 (46) 0.22 ± 0.24 0.70 to 0.26 .36
Crypt architectural irregularities 0.17 ± 0.19 (42) 0.23 ± 0.19 (46) 0.053 ± 0.160 0.37 to 0.27 .74
NOTE. Subjects who did not have biopsy and had inadequate biopsy at week 0 or 8 were excluded from this analysis.
aValues are least squares mean ± standard error (n).
bValues are least squares mean ± standard error.
cAnalysis of covariance models were adjusted for stratiﬁcation factors at randomization.
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